Ben Xi Shi

Researchers are investigating whether Extract of Ginkgo Biloba Leaves Tablets can help improve thinking and memory in people aged 55 years and older who have had an ischemic stroke, which is caused by a blocked blood vessel in the brain. This phase 4 clinical trial is designed to assess both the effectiveness and safety of this treatment when added to the usual care for stroke recovery. Participants must have had a mild stroke confirmed by an MRI scan and show signs of cognitive impairment. The study takes place at multiple hospitals across China. Participants will be randomly assigned to one of two groups: one group will receive Extract of Ginkgo Biloba Leaves Tablets at a dose of 240 mg daily, divided into three doses of two 40 mg tablets each, along with their standard post-stroke care for 52 weeks. The other group will receive only the standard care recommended by the Chinese Stroke Association. The trial is open-label, meaning both the researchers and participants know which treatment is given. Throughout the year-long study, participants will visit the clinic at 4, 26, and 52 weeks after starting treatment for checkups and testing. Researchers will evaluate changes in cognitive function using tests such as the Montreal Cognitive Assessment, Trail Making Test, Symbol Digit Modalities Test, and Verbal Fluency Test. They will also monitor neurological impairment and any new stroke events. Follow-up phone calls will occur at 12 and 38 weeks to support ongoing monitoring and safety assessments.

Researchers are studying extensive intraductal carcinoma of the breast, a type of breast cancer where at least 25% of the tumor is ductal carcinoma in situ (DCIS) scattered within or around invasive cancer. This form is less sensitive to radiotherapy and has a higher risk of tumor recurrence after breast-conserving surgery. The study aims to compare postoperative disease-free survival and quality of life between two surgical options: modified radical mastectomy and expanded Mckissock surgery. Expanded Mckissock surgery involves a carefully planned incision based on imaging and patient preferences, preserving the nipple-areola complex while removing the breast gland. After general anesthesia, surgeons remove the gland while keeping the nipple and areola intact, check the tissue edges for cancer, and perform lymph node biopsy or cleaning. The breast is reshaped using flaps, and drainage tubes are placed. The modified radical mastectomy involves removing the breast after marking the tumor boundaries under anesthesia, followed by reshaping and drainage tube placement. Participants will be monitored for disease-free survival over five years. Assessments include imaging, biopsy results, and quality-of-life evaluations. Researchers will track cancer recurrence and patient well-being following surgery. This prospective cohort study will help determine how the two surgical techniques compare in outcomes and patient quality of life after treatment for extensive intraductal carcinoma of the breast.

Researchers are evaluating the effectiveness of drug-eluting stents combined with aggressive medical treatment compared to standard medical treatment alone in preventing stroke recurrence within one year for patients with symptomatic intracranial atherosclerotic disease. This prospective, multi-center, randomized trial focuses on patients who have experienced ischemic stroke related to severe narrowing of major intracranial arteries. The study aims to assess stroke and death rates within 30 days of enrollment or revascularization procedures, as well as ischemic strokes occurring up to one year after enrollment. Participants are randomly assigned to receive either a drug-eluting sirolimus stent implanted using a balloon-expandable system along with aggressive medical treatment or standard medical treatment alone. Aggressive treatment includes dual antiplatelet therapy with aspirin plus clopidogrel or ticagrelor for six months, while standard treatment involves similar medications for three months. Both groups receive risk factor management addressing hypertension, diabetes, lipid metabolism, smoking, and exercise. The stent system features a rapid exchange catheter with a semi-compliant balloon for intracranial artery treatment. During the study, participants undergo regular monitoring to track any strokes, death, or bleeding complications over 12 months. Key assessments include clinical evaluations and safety monitoring for bleeding severity using the GUSTO score. The trial measures the occurrence of stroke or death within the first 30 days after enrollment or revascularization and ischemic strokes in the treated artery territory from 31 days to one year. The total follow-up period lasts 12 months to evaluate the long-term outcomes of these treatments.

This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial. The goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke. Participants will be required to receive 24 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo.

Researchers are evaluating the safety and effectiveness of QD202 injection in patients who have experienced an acute ischemic stroke and are undergoing thrombolysis, but not endovascular thrombectomy. This is a Phase II randomized, double-blind, placebo-controlled study involving up to 120 male and female participants aged 18 to 85 years. The trial aims to measure safety and tolerance over an average of 90 days following treatment. Participants will receive either QD202, a 19 amino acid peptide designed to cross the blood-brain barrier, or a matching placebo. The assigned treatment is given as a 60-minute intravenous infusion after completing the thrombolysis procedure, during the first five days of the study. Follow-up assessments take place on Day 7 or at discharge, Day 30, and at the study's end on Day 90. Throughout the study, participants will undergo neurological evaluations and safety monitoring, including clinical assessments related to stroke recovery. Researchers will collect data on treatment safety and how well patients tolerate the infusion. The total involvement period for each participant is approximately 90 days, allowing for careful observation and measurement of outcomes after the intervention.

Chronic kidney disease (CKD) is a serious health concern, with primary glomerulonephritis being a leading cause in 50% to 60% of cases. This research aims to evaluate the safety and effectiveness of Huaiqihuang Granule, a traditional Chinese herbal medicine, in treating patients with stage 3 CKD caused by primary glomerulonephritis. The study is a phase 4, multicenter, randomized, double-blind, positive-drug controlled trial conducted across about 40 top hospitals in China. Participants will be randomly assigned to receive either Huaiqihuang Granules or Valsartan capsules. The Huaiqihuang group will take 2 bags of granules three times daily, while the Valsartan group will take 80 mg capsules once daily, with each group receiving a simulant of the other drug to maintain blinding. All medications are taken orally over a treatment period of 48 weeks, with follow-up visits scheduled at weeks 0, 8, 16, 24, 32, 40, and 48. During the study, participants will be monitored through regular visits to assess kidney function and overall health. The main outcome measured is the rate of change in estimated glomerular filtration rate (eGFR) from the start to week 48. The study also tracks safety and adherence, ensuring participants meet the eligibility requirements and receive ongoing evaluation throughout the nearly one-year participation period.

Researchers are evaluating the efficacy and safety of Shuxuening injection as an additional treatment to intravenous thrombolysis in patients with acute ischemic stroke. This multicenter, randomized, double-blind, placebo-controlled phase 3 trial involves patients aged 18 to 100 years who have experienced an ischemic stroke and can be treated within 6 hours of symptom onset. The study aims to improve functional outcomes by reducing brain cell death after stroke using this multi-target neuroprotective agent alongside the standard clot-busting therapy. Participants are randomly assigned in a 1:1 ratio to receive either Shuxuening injection or a placebo. Both groups receive a daily intravenous drip of 20 ml of the study drug or placebo combined with 250 ml of 0.9% sodium chloride injection for 10 to 14 days. The treatment starts as soon as possible after intravenous thrombolysis therapy, and the study compares these two groups to assess differences in recovery and safety. During the trial, researchers will monitor participants for 90 days after randomization. They will assess the primary outcome by measuring the proportion of patients achieving a modified Rankin Scale (mRS) score of 0 to 1, indicating good functional recovery. Safety will be evaluated by tracking adverse events over the same 90-day period. Participants will be closely followed with clinical evaluations to understand the effects and tolerability of Shuxuening injection in stroke recovery.